Firefly Neuroscience shares are trading higher after the company announced that it advanced research using Resting EEG/Cognitive EEG brain scans collected on its FDA-510(k)-cleared Evoke System to potentially distinguish between the three main subtypes of attention-deficit/hyperactivity disorder.